VIC
VIC supports rapid-pace, high-impact research initiatives that are in the process of safely transitioning from the research lab to patients. It aims to accelerate discovery and development of new products addressing unmet clinical needs, focusing on modulating the immune system for therapeutic benefit in cancer, infectious, and immune-mediated diseases. VIC collaborates with academic and industry scientists worldwide, developing products like biologic immunotherapies, vaccines, microencapsulants, and immune cell therapies.
Industries
Nr. of Employees
small (1-50)
VIC
Charlestown, Massachusetts, United States, North America
Products
Biologic immunotherapy candidates for cancer
Novel biologic immunotherapy candidates under preclinical and early clinical development intended for specific cancer indications.
Vaccine candidate for HPV-associated cancers
A prophylactic or therapeutic vaccine candidate targeting human papillomavirus–related malignancies, advanced through preclinical development.
Microencapsulation platform for allogeneic transplantation
Microencapsulant technology designed to enable allogeneic cell or tissue transplantation with local immune protection to reduce or avoid systemic immunosuppression.
Allogeneic B cell–based therapy for neurodegenerative injury
Cell therapy product concept using donor B cell infusions intended to modulate inflammation and provide neuroprotective effects in conditions such as ALS and intracranial hemorrhage.
Handheld near-infrared laser adjuvant device
A small, lower-cost near-infrared laser device developed for use as a physical adjuvant to enhance intradermal vaccine responses with reduced sensitivity to skin pigmentation.
mRNA nanoparticle therapeutic strategies
Preclinical approaches combining mRNA nanoparticle delivery with immune checkpoint modulation to restore tumor suppressor function and enhance antitumor immunity.
Biologic immunotherapy candidates for cancer
Novel biologic immunotherapy candidates under preclinical and early clinical development intended for specific cancer indications.
Vaccine candidate for HPV-associated cancers
A prophylactic or therapeutic vaccine candidate targeting human papillomavirus–related malignancies, advanced through preclinical development.
Microencapsulation platform for allogeneic transplantation
Microencapsulant technology designed to enable allogeneic cell or tissue transplantation with local immune protection to reduce or avoid systemic immunosuppression.
Allogeneic B cell–based therapy for neurodegenerative injury
Cell therapy product concept using donor B cell infusions intended to modulate inflammation and provide neuroprotective effects in conditions such as ALS and intracranial hemorrhage.
Handheld near-infrared laser adjuvant device
A small, lower-cost near-infrared laser device developed for use as a physical adjuvant to enhance intradermal vaccine responses with reduced sensitivity to skin pigmentation.
mRNA nanoparticle therapeutic strategies
Preclinical approaches combining mRNA nanoparticle delivery with immune checkpoint modulation to restore tumor suppressor function and enhance antitumor immunity.
Services
Translational acceleration from discovery to early clinical testing
Programmatic support and project management to move candidate vaccines and immunotherapies from laboratory discovery through preclinical studies into first-in-human testing and partner handoff.
Collaborative preclinical research and platform development
Collaborative laboratory research programs including preclinical efficacy testing, immune profiling, and platform engineering for vaccines, cell therapies, and delivery systems.
Translational acceleration from discovery to early clinical testing
Programmatic support and project management to move candidate vaccines and immunotherapies from laboratory discovery through preclinical studies into first-in-human testing and partner handoff.
Collaborative preclinical research and platform development
Collaborative laboratory research programs including preclinical efficacy testing, immune profiling, and platform engineering for vaccines, cell therapies, and delivery systems.
Expertise Areas
- Vaccine development and clinical translation
- Immunotherapy and cell therapy development
- High-dimensional immunology and immune profiling
- RNA delivery and nanomedicine
Key Technologies
- mRNA nanoparticle delivery
- Extracellular vesicle (EV)-based RNA delivery
- Allogeneic B cell therapy
- Near-infrared laser adjuvant devices